Showing 681 - 700 results of 1,123 for search '"Prostate"', query time: 0.06s Refine Results
  1. 681

    Study on Apoptosis of Prostate Cancer Cells Induced by IκBα Overexpression Synergistic with Poly (Lactic-Co-Glycolic Acid)-Curcumin Nanoparticles by Hui Guo, Jianwen Huang, Hongbin Li, Ranxing Yang, Rong Chen

    Published 2021-01-01
    “…To investigate the synergistic effects of IκBα overexpression and poly (lactic-co-glycolic acid)-curcumin nanoparticles (PLGA-Cur-NPs) on prostate cancer (PC) and reveal the underlying mechanisms of cooperative sensitization induced by curcumin. …”
    Get full text
    Article
  2. 682

    Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer by Amit D. Raval, Malcolm D. Mattes, Suresh Madhavan, Xiaoyun Pan, Wenhui Wei, Usha Sambamoorthi

    Published 2016-01-01
    “…To examine the association between metformin use and cancer stage at diagnosis among elderly men with preexisting diabetes mellitus and incident prostate cancer. Methods. This study used a population-based observational cohort of elderly men (≥66 years) with preexisting diabetes and incident prostate cancer between 2008 and 2009 (N=2,652). …”
    Get full text
    Article
  3. 683
  4. 684
  5. 685
  6. 686

    The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia by Yoshinori Tanaka, Yasushi Tanuma, Naoya Masumori

    Published 2017-01-01
    “…The persistence of silodosin and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in real-life clinical practice. …”
    Get full text
    Article
  7. 687
  8. 688

    PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial by Mark N. Stein, Ecaterina E. Dumbrava, Benjamin A. Teply, Usama S. Gergis, Martin E. Guiterrez, Ran Reshef, Sumit K. Subudhi, Céline F. Jacquemont, Joseph H. Senesac, J. Henri Bayle, Charity D. Scripture, Monica S. Chatwal, Mehmet A. Bilen, Walter M. Stadler, Carlos R. Becerra

    Published 2024-12-01
    “…Two mCRPC patients experienced partial responses (one unconfirmed), and 56% of mCRPC patients achieved ≥50% reduction in prostate-specific antigen. BPX-601 cell expansion, long-term persistence in peripheral blood, and tumor infiltration were observed. …”
    Get full text
    Article
  9. 689

    Delivery Parameter Variations and Early Clinical Outcomes of Volumetric Modulated Arc Therapy for 31 Prostate Cancer Patients: An Intercomparison of Three Treatment Planning Systems by Shinichi Tsutsumi, Masako N. Hosono, Daisaku Tatsumi, Yoshitaka Miki, Yutaka Masuoka, Ryo Ogino, Kentaro Ishii, Yasuhiko Shimatani, Yukio Miki

    Published 2013-01-01
    “…We created volumetric modulated arc therapy (VMAT) plans for 31 prostate cancer patients using one of three treatment planning systems (TPSs)—ERGO++, Monaco, or Pinnacle—and then treated those patients. …”
    Get full text
    Article
  10. 690
  11. 691
  12. 692
  13. 693
  14. 694
  15. 695
  16. 696

    Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. by Stephanie J Weinstein, Dominick Parisi, Alison M Mondul, Tracy M Layne, Jiaqi Huang, Rachael Z Stolzenberg-Solomon, Regina G Ziegler, Mark P Purdue, Wen-Yi Huang, Christian C Abnet, Neal D Freedman, Kai Yu, Demetrius Albanes

    Published 2024-01-01
    “…We examined interactions between serum 25-hydroxyvitamin D [25(OH)D], the Gc isoforms Gc1-1, Gc1-2, and Gc2-2, and cancer risk within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial cohort based on 3,795 cases and 3,856 controls. …”
    Get full text
    Article
  17. 697
  18. 698

    The PROCAN-B study protocol: Early diagnosis of PROstate CANcer for Black men-a community-centred participatory approach in Scotland and the North-East of England. by Floor Christie-de Jong, Judith Eberhardt, Jonathan Ling, Marie Kotzur, Olugbenga Samuel Oyeniyi, Lawrence Nnyanzi, John Kabuye, Martin Kalemba, Kathryn A Robb

    Published 2024-01-01
    “…<h4>Background</h4>Prostate cancer is the most common cancer in the UK and Black African-Caribbean men are twice as likely to develop prostate cancer as white men. …”
    Get full text
    Article
  19. 699

    Tale of two zones: investigating the clinical outcomes and research gaps in peripheral and transition zone prostate cancer through a systematic review and meta-analysis by Pedro Oliveira, Robert G Bristow, Ananya Choudhury, Ashwin Sachdeva, Noel Clarke, Hitesh Mistry, Amin Ali, Thiraviyam Elumalai, BhanuPrasad Venkatesulu, Lauren Hekman, Esther Baena

    Published 2024-07-01
    “…Objective To assess pathological characteristics, clinical features and outcomes of patients diagnosed with peripheral zone (PZ) and transition zone (TZ) prostate cancer after prostatectomy.Methods and analysis We systematically reviewed PubMed, EMBASE and MEDLINE. …”
    Get full text
    Article
  20. 700